Dr. John F. Dipersio, MD
Medical Oncology (Medical Oncology Physician)
4500 Forest Park Ave, Div Im Bone Marrow Transplant, 5th, 6th, 8th Fl
Saint Louis, MO 63108
- Medicare participating
At a glance
- Medical school
- University of Rochester School of Medicine and Dentistry (1980)
- Years since graduation
- 46
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 346
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1980Medical school: University of Rochester School of Medicine and Dentistry
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MO license 105204
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Barnes Jewish Hospital Saint Louis, MO
- Barnes-Jewish West County Hospital Creve Coeur, MO
- Christian Hospital Northeast Saint Louis, MO
- Barnes-Jewish St Peters Hospital Saint Peters, MO
Medical groups
- Washington University (3,029 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 346
- Services billed
- 37,097
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 8,200 | 15 |
| Injection, fosaprepitant, 1 mg | 7,650 | 22 |
| Injection, azacitidine, 1 mg | 3,400 | 12 |
| Injection, denosumab, 1 mg | 1,920 | 11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,160 | 48 |
| Injection, palonosetron hcl, 25 mcg | 700 | 34 |
| Established patient office or other outpatient visit, 30-39 minutes | 342 | 127 |
| Injection, granisetron hydrochloride, 100 mcg | 340 | 19 |
| Injection, ondansetron hydrochloride, per 1 mg | 304 | 11 |
| Insertion of needle into vein for collection of blood sample | 300 | 117 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Jakafi (ruxolitinib phosphate) | 153 |
| Acyclovir Other prescribers in Saint Louis, MO | 136 |
| Prednisone Other prescribers in Saint Louis, MO | 107 |
| Fluconazole Other prescribers in Saint Louis, MO | 84 |
| Oxycodone Hcl Other prescribers in Saint Louis, MO | 72 |
| Pantoprazole Sodium Other prescribers in Saint Louis, MO | 58 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Saint Louis, MO | 57 |
| Ciprofloxacin Hcl Other prescribers in Saint Louis, MO | 50 |
| Allopurinol Other prescribers in Saint Louis, MO | 41 |
| Calquence (acalabrutinib maleate) | 40 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 8 payments worth $6,098 in total to this clinician.
| Geron Corporation | $3,380 |
|---|---|
| Janssen Scientific Affairs, LLC | $2,664 |
| Pfizer Inc. | $54.04 |
| Consulting Fee | $5,428 |
|---|---|
| Travel and Lodging | $363 |
| Food and Beverage | $307 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Geron Corporation Dec 11, 2025 | Consulting Fee IMETELSTAT · HEMATOLOGY | $2,925 |
| Janssen Scientific Affairs, LLC Sep 23, 2025 | Consulting Fee | $2,503 |
| Geron Corporation Dec 5, 2025 | Travel and Lodging IMETELSTAT · HEMATOLOGY · travel to ORLANDO, FL | $363 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $214,008 in research payments for these studies, mostly to the institutions running them.
- A phase 1/2, open-label, dose-escalation and dose-expansion cohort study of SNDX-5613 in patients with relapsed/refractory leukemias, including those harboring an mll/KMT2A gene rearrangement or nucleophosmin 1 (NPM1)…
Syndax Pharmaceuticals, Inc. - Expanded access program FORSNDX-5613IN patients with relapsed/refractory acute leukemias with genetic alterations associated with hoxa overexpression
Syndax Pharmaceuticals, Inc. - TAK-012-1501
Takeda Pharmaceuticals U.S.A., Inc. - A phase 1, open-label, dose-escalation, and dose-expansion study to evaluate safety, tolerability, and clinical activity OFSNDX-5613IN combination with intensive chemotherapy in participants with newly diagnosed acute…
Syndax Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.